Lilly(Eli) & Company

NYSE: LLY
$764.71
-$13.91 (-1.8%)
Closing Price on December 18, 2024

LLY Articles

24/7 Wall St. has put together a preview of the most prominent earnings reports this week, including Amazon.com, AT&T and General Electric.
The December 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Dermira shares made a handy gain to close out the week after it was announced that Eli Lilly would be acquiring the firm.
The top analyst upgrades, downgrades and initiations for the final trading days of 2019 included Activision Blizzard, Amazon.com, Apple, Boeing, Eli Lilly, Johnson & Johnson, Lennar, Nio, Nvidia...
The December 13 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
The FDA has approved Allergan's treatment for migraines in adults. The drug is the first of its class to obtain FDA approval, but the new drug will compete with other recently released treatments for...
Wednesday's top analyst upgrades, downgrades and initiations included Activision Blizzard, Datadog, Delta Air Lines, Eli Lilly, FedEx, Halliburton, Kinder Morgan, Skechers, Teladoc and Waste...
The November 29 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
The November 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
The October 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
The October 15 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Eli Lilly shares retreated after it released mixed third-quarter financial results before the markets opened on Wednesday.
Credit Suisse and Merrill Lynch made calls in the biotech and pharmaceutical space last week, ahead of coming earnings reports.
Thursday's top analyst upgrades, downgrades and initiations included Abbott Laboratories, CSX, IBM, Netflix, Occidental Petroleum, Whiting Petroleum, Amgen, Gilead Sciences, Merck and Pfizer.
The September 30 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.